Early research on a drug to prevent breast cancer
https://www.facingourrisk.org/XRAY/breast-cancer-prevention-drug
Full article: https://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4118.html
Many researchers are interested in non-surgical options to reduce the higher-than-average risk of developing breast cancer in BRCA mutation carriers. This research study identified a type of drug, called a “RANK ligand inhibitor,” that may prevent breast cancer. Among mice that were genetically engineered to have no BRCA1 genes, those that were given the drug developed tumors less frequently than those that did not. While this is an exciting early study for BRCA mutation carriers, more work and human clinical trials need to be done before this can be used as a prevention therapy in humans. (7/12/16)
Update added 11/24/19: The RANK ligand inhibitor, denosumab is currently being studied as a possible breast and ovarian cancer preventive agent in human clinical trials.
Questions To Ask Your Health Care Provider
- I am a BRCA1 mutation carrier. What can I do to lower my breast cancer risk?
- I am a BRCA mutation carrier who has not had cancer. Are there clinical trials looking at new ways to prevent cancer, and do I qualify for them?
- Are there currently drugs available to lower the risk of breast cancer in BRCA mutation carriers?
Open Clinical Trials
The following are breast cancer screening or prevention studies enrolling people at high risk for breast cancer.
- NCT04067726: Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT). This study is looking at the drug denosumab to learn if it can reduce breast density in high-risk premenopausal women who have dense breasts.
- The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations. This study seeks to improve researchers’ understanding of how hormonal, reproductive and lifestyle factors may be associated with cancer in high-risk people.
- NCT02620852: Women Informed to Screen Depending on Measures of Risk (WISDOM) study. The goal of this study is to determine if breast cancer screening can be improved by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all annual approach.
-
NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. This study is testing a new vaccine to lower the risk of breast cancer in high-risk women with an inherited mutation in BRCA1, BRCA2 or PALB2.
Additional risk-management clinical trials for people at high risk for breast cancer may be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.